FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283399797> ?p ?o ?g. }

• W4283399797 endingPage "1949" @default.
• W4283399797 startingPage "1948" @default.
• W4283399797 abstract "Background: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin’s lymphoma (NHL) with a generally aggressive, albeit heterogeneous, clinical course. It can present either with asymptomatic monoclonal lymphocytosis or non-bulky nodal/extra nodal disease with minimal symptoms or with a progressive generalized lymphadenopathy, cytopenia, splenomegaly and extra-nodal disease. Despite the paradigm shift in the treatment landscape, there is still a subset of patients with a worse prognosis. Novel surrogate markers had been emerging in other entities such as POD24 (progression of disease within 2 years) in follicular lymphoma, which is not still studied in MCL. Aims: Evaluate the prognostic factor of POD within 12months (POD12) and 24months (POD24) after first line treatment in MCL patients Methods: We retrospectively evaluated 118 patients (pts) with MCL between Jan/2010 and Dec/2020. Survival analysis was evaluated using Kaplan-Meier curves and the identification of predictive factors by the Cox regression method. Results: 83 (70.3%) pts were male and the median age at diagnosis was 67 years [39-89]. 114 (96.6%) pts had stage III/IV at diagnosis, 85.6% ECOG <2, 81.4% bone marrow involvement, 79.5% diffuse lymphadenopathies, 45.8% B symptoms, 33.9% splenomegaly, 30.5% leukemic phase, 25.4% extra-nodal disease, 25.4% gastrointestinal involvement and 23.7% bulky disease (>5cm). The median LDH at diagnosis was 212U/L. According to the MIPI score, 82pts (69.5%) were low risk, 13 (11.9%) intermediate and 22 (18.6%) high risk. The median lines of therapy was 2 [1-5] and 32pts (27.1%) underwent autologous stem cell transplant after first line therapy. Overall survival (OS) at 2 and 5 years was 81% and 56.6%. POD12 and POD24 occurred in 39 dts (33.1%) and 56 (47.5%), respectively. Patients with POD12 had a 2‐year OS of 44.5% and 5‐year OS of 18.4% compared to 98.7% and 75% for patients without early POD12, respectively. Regarding POD24, 5‐year OS of 20.9% compared to 84.4%, respectively, for patients without early POD24.The Kaplan‐Meier curve showed an inferior OS for patients with early POD compared to those not relapsing within 12 months and/or 24 months (P < 0.001) [figure ​1 and 2]. Univariable analysis showed that ECOG ≥2, leukemic phase, elevated LDH, MIPI score, POD12 and POD24 were associated with inferior OS. In multivariable analysis, clinical factors predictive of inferior OS were POD12, POD24, high risk MIPI, elevated LDH and ECOG ≥2. Image:Summary/Conclusion: POD12 and POD24 are associated with unfavorable outcomes and worse OS. These results support the potential to use these criteria as primary surrogate endpoints. Survival analysis did not allow us to conclude which of the endpoints have the greatest discriminative power in OS, so prospective studies with larger sampling will be necessary." @default.
• W4283399797 created "2022-06-25" @default.
• W4283399797 creator A5031697069 @default.
• W4283399797 creator A5034189673 @default.
• W4283399797 creator A5045006403 @default.
• W4283399797 creator A5047346113 @default.
• W4283399797 creator A5047657358 @default.
• W4283399797 creator A5049279419 @default.
• W4283399797 creator A5054897950 @default.
• W4283399797 creator A5056762017 @default.
• W4283399797 creator A5076384027 @default.
• W4283399797 creator A5086247792 @default.
• W4283399797 creator A5087686017 @default.
• W4283399797 date "2022-06-01" @default.
• W4283399797 modified "2023-09-30" @default.
• W4283399797 title "PB2077: POD12 AND POD24 – A NEW SURROGATE MARKER IN MANTLE CELL LYMPHOMA TREATMENT?" @default.
• W4283399797 doi "https://doi.org/10.1097/01.hs9.0000851140.58553.2a" @default.
• W4283399797 hasPublicationYear "2022" @default.
• W4283399797 type Work @default.
• W4283399797 citedByCount "0" @default.
• W4283399797 crossrefType "journal-article" @default.
• W4283399797 hasAuthorship W4283399797A5031697069 @default.
• W4283399797 hasAuthorship W4283399797A5034189673 @default.
• W4283399797 hasAuthorship W4283399797A5045006403 @default.
• W4283399797 hasAuthorship W4283399797A5047346113 @default.
• W4283399797 hasAuthorship W4283399797A5047657358 @default.
• W4283399797 hasAuthorship W4283399797A5049279419 @default.
• W4283399797 hasAuthorship W4283399797A5054897950 @default.
• W4283399797 hasAuthorship W4283399797A5056762017 @default.
• W4283399797 hasAuthorship W4283399797A5076384027 @default.
• W4283399797 hasAuthorship W4283399797A5086247792 @default.
• W4283399797 hasAuthorship W4283399797A5087686017 @default.
• W4283399797 hasBestOaLocation W42833997971 @default.
• W4283399797 hasConcept C126322002 @default.
• W4283399797 hasConcept C141341695 @default.
• W4283399797 hasConcept C143998085 @default.
• W4283399797 hasConcept C207103383 @default.
• W4283399797 hasConcept C2777058707 @default.
• W4283399797 hasConcept C2777525834 @default.
• W4283399797 hasConcept C2777910003 @default.
• W4283399797 hasConcept C2779338263 @default.
• W4283399797 hasConcept C2779714933 @default.
• W4283399797 hasConcept C2780007613 @default.
• W4283399797 hasConcept C2780126324 @default.
• W4283399797 hasConcept C2780366003 @default.
• W4283399797 hasConcept C2780653079 @default.
• W4283399797 hasConcept C2781442060 @default.
• W4283399797 hasConcept C44249647 @default.
• W4283399797 hasConcept C71924100 @default.
• W4283399797 hasConcept C90924648 @default.
• W4283399797 hasConceptScore W4283399797C126322002 @default.
• W4283399797 hasConceptScore W4283399797C141341695 @default.
• W4283399797 hasConceptScore W4283399797C143998085 @default.
• W4283399797 hasConceptScore W4283399797C207103383 @default.
• W4283399797 hasConceptScore W4283399797C2777058707 @default.
• W4283399797 hasConceptScore W4283399797C2777525834 @default.
• W4283399797 hasConceptScore W4283399797C2777910003 @default.
• W4283399797 hasConceptScore W4283399797C2779338263 @default.
• W4283399797 hasConceptScore W4283399797C2779714933 @default.
• W4283399797 hasConceptScore W4283399797C2780007613 @default.
• W4283399797 hasConceptScore W4283399797C2780126324 @default.
• W4283399797 hasConceptScore W4283399797C2780366003 @default.
• W4283399797 hasConceptScore W4283399797C2780653079 @default.
• W4283399797 hasConceptScore W4283399797C2781442060 @default.
• W4283399797 hasConceptScore W4283399797C44249647 @default.
• W4283399797 hasConceptScore W4283399797C71924100 @default.
• W4283399797 hasConceptScore W4283399797C90924648 @default.
• W4283399797 hasLocation W42833997971 @default.
• W4283399797 hasLocation W42833997972 @default.
• W4283399797 hasLocation W42833997973 @default.
• W4283399797 hasLocation W42833997974 @default.
• W4283399797 hasOpenAccess W4283399797 @default.
• W4283399797 hasPrimaryLocation W42833997971 @default.
• W4283399797 hasRelatedWork W1970884884 @default.
• W4283399797 hasRelatedWork W1997629499 @default.
• W4283399797 hasRelatedWork W2112679438 @default.
• W4283399797 hasRelatedWork W2148093607 @default.
• W4283399797 hasRelatedWork W2519666010 @default.
• W4283399797 hasRelatedWork W2551649272 @default.
• W4283399797 hasRelatedWork W2952834020 @default.
• W4283399797 hasRelatedWork W2979695321 @default.
• W4283399797 hasRelatedWork W4283399797 @default.
• W4283399797 hasRelatedWork W981324396 @default.
• W4283399797 hasVolume "6" @default.
• W4283399797 isParatext "false" @default.
• W4283399797 isRetracted "false" @default.
• W4283399797 workType "article" @default.